Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options?
about
Evaluation of potential anti-toxoplasmosis efficiency of combined traditional herbs in a mouse modelMaternal and congenital toxoplasmosis, currently available and novel therapies in horizonNovel Synergistic Protective Efficacy of Atovaquone and Diclazuril on Fetal-Maternal ToxoplasmosisToxoplasmosis complications and novel therapeutic synergism combination of diclazuril plus atovaquone."Blind periods" in screening for toxoplasmosis in pregnancy in Austria - a debate.Pyrimidine as constituent of natural biologically active compounds.Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells.Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents.Symptomatic toxoplasma infection due to congenital and postnatally acquired infectionOral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondiiPrevention and treatment of congenital toxoplasmosis.Evaluation of Propranolol Effect on Experimental Acute and Chronic Toxoplasmosis Using Quantitative PCR.A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).Si-Accumulation In Artemisia annua Glandular Trichomes Increases Artemisinin Concentration, but Does Not Interfere In the Impairment of Toxoplasma gondii Growth.N-[2-Chloro-6-(4-chloro-6-methoxy-pyrimidin-2-ylsulfan-yl)benz-yl]-3,4-dimethyl-aniline.4-Chloro-2-{3-chloro-2-[(3,5-dimethyl-piperidin-1-yl)meth-yl]phenyl-sulfan-yl}-6-methoxy-pyrimidine.The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation.Fetomaternal and Pediatric Toxoplasmosis.Cu(II) /TEMPO-promoted one-pot synthesis of highly substituted pyrimidines from amino acid esters.Targeting Channels and Transporters in Protozoan Parasite Infections.
P2860
Q33827792-643FF6F5-F08E-4CE6-9EFD-DDDD4C4895A5Q33943894-1673763E-A3F1-4B77-885D-0D7C6D42CDC5Q34149967-7FECE16A-90B8-42D1-B63A-9FB5DCFF2F2EQ34180868-C6FC0C79-17EF-41DD-9CA4-A820CE9893D2Q34271439-E60EE53C-4489-4742-8BE4-A82BAFA4AAFDQ34595236-DFD83F65-5DAF-4BB9-A96C-99485F246A59Q35954233-832ADEAE-52D1-492A-9EE8-276E6D4DD6CDQ36117950-DC8AA3FB-DE7D-4F0A-AC98-011858CC0E53Q36152950-FD558DCA-AA90-4293-9B0E-A3C834E32DA0Q36160414-6431D952-6AE1-481B-99E2-7FCBA5DB3C93Q36777857-2A17C14E-D9E3-417C-9BE3-D09EA035660EQ37428612-9FCB6856-C9A9-4473-9971-060A12A5850DQ37594988-11BDECDB-8724-459B-82D4-6F32DAC3F99CQ40512307-4EC21980-2B96-406D-A573-CEBD2ED4EABAQ41934620-27F3F957-FD75-4AC6-8198-F4BE859AD052Q42023035-F29C6770-BF84-4DBB-AA38-C6C201BE05E4Q47449818-098D0B93-6540-417D-8A00-70286FB4C626Q47565444-1DC3E839-13C7-4337-A893-952FA9CE02AAQ51036951-F1A6D578-21F7-4589-82BF-D1995E2BD4ACQ52594992-6E77EFCD-E115-44B4-B521-413AEC546525
P2860
Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options?
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Sulfadiazine and pyrimethamine ...... asmosis: what are the options?
@ast
Sulfadiazine and pyrimethamine ...... asmosis: what are the options?
@en
type
label
Sulfadiazine and pyrimethamine ...... asmosis: what are the options?
@ast
Sulfadiazine and pyrimethamine ...... asmosis: what are the options?
@en
prefLabel
Sulfadiazine and pyrimethamine ...... asmosis: what are the options?
@ast
Sulfadiazine and pyrimethamine ...... asmosis: what are the options?
@en
P2860
P921
P356
P1476
Sulfadiazine and pyrimethamine ...... asmosis: what are the options?
@en
P2093
Dorte Remmer Schmidt
P2860
P304
P356
10.1586/14787210.1.1.175
P577
2003-06-01T00:00:00Z